Clinical trials: Metastases, Neoplasm
Bone Metastases, Cancer Survivor
Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases
This randomized pilot trial studies telemonitoring after surgery to preserve limb function in optimizing mobility in cancer survivors with cancer spread to the bone.
- Conditions
- Bone Metastases, Cancer Survivor, Metastatic Malignant Neoplasm in the Bone
- Trial name
- NCT02715856
- Testing
- Monitoring Device, Physical Activity Measurement, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Carcinoma
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
- Conditions
- Cancer, Carcinoma, Head and Neck Cancer, Metastases
- Trial name
- NCT00446446
- Testing
- Panitumumab
- Volunteers
- 52 people
- Sponsor
- Amgen
Cerebral Edema, Brain Metastases
Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)
Primary Objectives: Pilot Portion: To determine the feasibility and safety of administering oral glyburide to non-diabetic patients receiving stereotactic radiosurgery (SRS) for newly diagnosed brain metastases.
- Trial name
- NCT02460874
- Testing
- Glyburide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Prostate Cancer, Bone Metastases
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Trial name
- NCT02582749
- Testing
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Ajjai Alva, MD
Brain Metastases, Adult
SIMT Stereotactic Radiosurgery Outcomes Study
The purpose of this study is to determine the effectiveness and efficiency of Single Isocenter Multi-target Stereotactic Radiosurgery (SIMT SRS) in patients with four or more brain metastases
- Trial name
- SIMT (NCT02886572)
- Testing
- Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Malignant Melanoma, Brain Metastases
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
This is a Phase 1 study of E6201 plus dabrafenib for the treatment of CNS metastases in BRAF V600-mutated metastatic melanoma. A total of up to N=28-34 subjects with melanoma metastasized to the CNS will be included.
- Trial name
- NCT03332589
- Testing
- E6201, E6201 plus dabrafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Spirita Oncology, LLC
Non-Small Cell Lung Cancer, Leptomeningeal Metastases
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or…
- Conditions
- Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases
- Trial name
- NCT02616393
- Testing
- Tesevatinib
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Kadmon Corporation, LLC
Breast Cancer, Bone Metastases
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone.
- Trial name
- NCT00566618
- Testing
- Dasatinib, Zoledronic Acid
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastases
A Proof-of-principle Study of HBO-SRS for Brain Metastases
Patients with brain metastases who are candidates for treatment with stereotactic radiosurgery (SRS) are potential study participants.
- Trial name
- NCT01850563
- Testing
- Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Brain Metastases, Breast Cancer
STAR Cape+BKM120 MBC With Brain Met
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer.
- Conditions
- Brain Metastases, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT02000882
- Testing
- BKM120, capecitabine, Trastuzumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- US Oncology Research
Thoracic Sarcomas, Thorasic Cancers
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Background: During recent years, cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X genes), have emerged as attractive targets for cancer immunotherapy.
- Conditions
- Thoracic Sarcomas, Thorasic Cancers, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura, Sarcoma
- Trial name
- NCT02054104
- Testing
- H1299 cell lysates, Cyclophosphamide, Celecoxib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT01285102
- Testing
- irinotecan-eluting beads, hepatic artery embolization
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fox Chase Cancer Center
Melanoma, Brain Metastases
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown to increase tumour shrinkage in animals…
- Trial name
- NCT02974803
- Testing
- Dabrafenib, Trametinib
- Where
- 6 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer Metastases, HER2 Positive Breast
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer.
- Trial name
- NCT02286843
- Testing
- 89Zr-trastuzumab, PET/CT scan, 89Zr-pertuzumab
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer With Metastases to the Liver
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
This is a multicentre, open labeled, controlled phase study designed to assess effectiveness of chemoembolization with LC Beads, both with and without systemic chemotherapy, in the treatment of unresectable liver metastases in…
- Trial name
- DEBIRI (NCT00932438)
- Testing
- LC beads loaded with Irinotecan, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Argentina
- Volunteers
- 70 people
- Sponsor
- University of Louisville
Metastatic Melanoma, Brain Metastases
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
This is a study to test the efficacy of using standard immune therapy for melanoma prior to stereotactic radiosurgery (ipilimumab induction), as compared to stereotactic radiosurgery followed by immune therapy.
- Trial name
- NCT02097732
- Testing
- Ipilimumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Carcinoma, Hepatocellular, Liver Metastases
Study to Evaluate VORTX Rx (Theresa)
Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors
- Trial name
- Theresa (NCT03741088)
- Testing
- VORTX Rx treatment
- Where
- 3 sites in Spain
- Volunteers
- 8 people
- Sponsor
- HistoSonics, Inc.
Neoplasms, Bone Metastases
Open Label Extension In Cancer Patients
To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label therapy.
- Trial name
- NCT00830180
- Testing
- Anti-NGF AB
- Where
- 23 sites in United States, Austria and 8 more
- Volunteers
- 41 people
- Sponsor
- Pfizer
Melanoma, Non-Small Cell Lung Cancer
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Brain Metastases
- Trial name
- NCT02085070
- Testing
- MK-3475
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Yale University